HADES Trademark

Trademark Overview

On Thursday, April 29, 2021, a trademark application was filed for HADES with the United States Patent and Trademark Office. The USPTO has given the HADES trademark a serial number of 79322626. The federal status of this trademark filing is REGISTERED as of Tuesday, October 18, 2022. This trademark is owned by Celeris Therapeutics GmbH. The HADES trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, scientific research, analysis, and testing of molecules, proteins and drugs and other chemical substances, in the field of early phase of drug development in the chemical industry; scientific services, namely, identifying new drug compounds from analysis of molecules, proteins and drugs and other chemical substances; information technology consulting services for the chemical and pharmaceutical industries, as well as related industries, namely, cosmetics and the food industry; Product quality testing [, authentication ] and quality control for others in the chemical and pharmaceutical industries for drug, protein, food chemistry, cosmetics and materials science development
hades

General Information

Serial Number79322626
Word MarkHADES
Filing DateThursday, April 29, 2021
Status700 - REGISTERED
Status DateTuesday, October 18, 2022
Registration Number6874656
Registration DateTuesday, October 18, 2022
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 2, 2022

Trademark Statements

Certificate of Correction for RegistrationIn the Statement, class 42 has been corrected per the Restriction date July 28, 2022, and per the fnote dated November 28, 2022.
Goods and ServicesScientific and technological services, namely, scientific research, analysis, and testing of molecules, proteins and drugs and other chemical substances, in the field of early phase of drug development in the chemical industry; scientific services, namely, identifying new drug compounds from analysis of molecules, proteins and drugs and other chemical substances; information technology consulting services for the chemical and pharmaceutical industries, as well as related industries, namely, cosmetics and the food industry; Product quality testing [, authentication ] and quality control for others in the chemical and pharmaceutical industries for drug, protein, food chemistry, cosmetics and materials science development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, October 18, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCeleris Therapeutics GmbH
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressAT
Party NameCeleris Therapeutics GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressAT
Party NameCeleris Therapeutics GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressAT

Trademark Events

Event DateEvent Description
Thursday, October 14, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, October 18, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 22, 2021APPLICATION FILING RECEIPT MAILED
Wednesday, December 29, 2021ASSIGNED TO EXAMINER
Tuesday, January 11, 2022NON-FINAL ACTION WRITTEN
Wednesday, January 12, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, February 2, 2022REFUSAL PROCESSED BY MPU
Thursday, February 3, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sunday, February 20, 2022REFUSAL PROCESSED BY IB
Friday, June 24, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 24, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 24, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 27, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 13, 2022NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, July 13, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, July 13, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, July 30, 2022LIMITATION OF GOODS RECEIVED FROM IB
Tuesday, August 2, 2022PUBLISHED FOR OPPOSITION
Tuesday, August 2, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 2, 2022NOTIFICATION PROCESSED BY IB
Tuesday, October 18, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, October 18, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, November 28, 2022CORRECTION UNDER SECTION 7 - PROCESSED
Tuesday, November 29, 2022LIMITATION FROM THE IB EXAMINED AND ENTERED
Tuesday, January 3, 2023NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Friday, February 10, 2023FINAL DISPOSITION PROCESSED
Wednesday, January 18, 2023FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, July 28, 2023PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Thursday, August 24, 2023INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Friday, February 10, 2023FINAL DISPOSITION NOTICE SENT TO IB
Monday, March 6, 2023FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, October 22, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, October 22, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, October 22, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, October 22, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED

Related Keywords

hades chemical drug industries scientific services namely pharmaceutical quality food development